Table 3 Selected studies presentation for venlafaxine
Study | Inclusion criteria | Age | Percent male | duration (weeks) | Treatment | Dosage (mg/day) | Patients per arm | Effect size (SD) | Response (%) | Dropouts (%) |
|---|---|---|---|---|---|---|---|---|---|---|
Khan et al. [36] | DSM-III, HAMD-D ≥ 20 | 41 41 41 | 0.44 0.44 0.44 | 6 | Venlafaxine Venlafaxine Venlafaxine Placebo | 75 75–225 150–375 | 23 22 22 26 | -0.8(0.1) -0.6(0.1) -0.7(0.1) |  | 0.21 0.15 |
Schweizer et al. [37] | DSM-III-R, Age 24–63 HAMD-D ≥ 20 | 46 46 46 | 0.60 0.60 0.60 | 6 | Venlafaxine Venlafaxine Venlafaxine Placebo | 75 225 375 | 15 15 14 16 | -0.6(0.1) -1.2(0.2) -1.1(0.2) |  | 0.43 0.57 |
Cunningham et al. [38] | DSM-III-R, Age ≥ 18 HAMD-D ≥ 20 | 41 | 0.33 | 6 | Venlafaxine Trazodone Placebo | 25–200 50–400 | 72 77 76 | -0.4(0.03) | 0.72 0.55 | 0.29 0.36 |
Schweizer et al. [39] | DSM-III-R, Age≥ 18 HAMD-D21 ≥ 20 | 41 | 0.31 | 6 | Imipramine Venlafaxine Placebo | 75–225 75–225 | 73 73 78 | -0.6(0.03) | 0.77 0.47 | 0.36 0.27 |
Cunningham et al. [40] | DSM-III-R, Age ≥ 18 HAMD-D ≥ 20 | 40 43 | 0.38 0.39 | 12 | Venlafaxine XR Venlafaxine IR Placebo | 75–150 75–150 | 97 96 100 | -0.5(0.02) -0.5(0.02) | 0.68 0.52 0.31 | 0.29 0.40 0.41 |
Thase et al. [41] | DSM-IV, Age ≥ 18 HAMD-D21 ≥ 20 | 40 | 0.39 | 8 | Venlafaxine XR Placebo | 75–225 | 91 100 | -0.6(0.02) | 0.58 0.29 | 0.27 0.40 |
Rudolph et al. [34] | DSM-IV, Age ≥ 18 HAMD-D21 ≥ 20 | 40 | 0.32 | 8 | Fluoxetine Venlafaxine XR Placebo | 20–60 75–225 | 103 100 98 | -0.1(0.02) | 0.57 0.42 | 0.19 0.21 |
Silverstone et al. [42] | DSM-IV, Age ≥ 18 HAMD-D21 ≥ 20 (on the first 17 items), Covi ≥ 8 | 41 | 0.39 | 12 | Fluoxetine Venlafaxine XR Placebo | 20–60 75–225 | 121 128 119 | -0.4(0.02) | 0.67 0.43 | 0.29 0.40 |
Globally | NA | 42 ± 2 | 0.43 | 8 ± 3 | Venlafaxine Placebo | 75–225 | 768 613 | -0.51(0.07) | 1.28(0.26) ** | -0.25(0.12) ** |